Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.946 – $1.06
Volume24,484
Market cap$15M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$14.95M
Price / earnings
—
Price / book
-0.73×
Price / sales
10.25×
EV / sales
26.74×
EV / EBITDA
-1.18×
Profitability
Earnings per share
-$1.97
Return on assets
-113.77%
Return on equity
137.64%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-1.34×
Current ratio
0.27×
Quick ratio
0.27×
Cash ratio
0.11×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.23M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PLUR, quarterly periods
Line item
Q1 FY2027 Sep 30, 2026
Q4 FY2026 Jun 30, 2026
Q3 FY2026 Mar 31, 2026
Q2 FY2026 Dec 31, 2025
Q1 FY2026 Sep 30, 2025
Q4 FY2025 Jun 30, 2025
Q3 FY2025 Mar 31, 2025
Q2 FY2025 Dec 31, 2024
Revenue
$759K
$335K
$167K
$198K
$316K
$398K
$427K
$185K
Cost of revenue
$339K
$139K
$111K
$112K
$201K
$191K
$291K
$74K
Gross profit
$420K
$196K
$56K
$86K
$115K
$207K
$136K
$111K
Selling, general and administrative
$2.32M
$2.37M
$2.63M
$2.77M
$2.53M
$2.83M
$2.49M
$2.14M
Research and development
$2.83M
$3.42M
$3.98M
$3.95M
$3.96M
$4.21M
$3.24M
$3.17M
Total operating expenses
$15.99M
$5.27M
$6.59M
$6.59M
$6.47M
$7.03M
$5.54M
$5.07M
Operating income
-$15.57M
-$5.07M
-$6.54M
-$6.51M
-$6.35M
-$6.83M
-$5.4M
-$4.96M
Interest expense
-$226K
-$235K
-$237K
-$231K
-$229K
-$233K
-$212K
-$211K
Income before taxes
-$15.38M
-$6.19M
-$6.18M
-$6.88M
-$6.14M
-$7.77M
-$6.34M
-$3.11M
Income taxes
$12K
-$1K
-$8K
-$8K
-$8K
-$5K
$0
$0
Net income
-$15.39M
-$6.19M
-$6.17M
-$6.87M
-$6.13M
-$7.77M
-$6.34M
-$3.11M
Net income attributable to common shareholders
-$10.39M
-$5.88M
-$5.55M
-$6.54M
-$5.85M
-$7.6M
-$6.15M
-$2.96M
EBITDA
-$15.44M
-$4.95M
-$6.41M
-$6.38M
-$6.22M
-$6.72M
-$5.33M
-$4.89M
Basic earnings per share
-$0.85
-$0.55
-$0.55
-$0.71
-$0.65
-$0.98
-$0.94
-$0.53
Diluted earnings per share
-$0.85
-$0.55
-$0.55
-$0.71
-$0.65
-$0.98
-$0.94
-$0.53
Recent news
Company coverage with links to the original publishers.
DarioHealth Corp. announced that its Chief Financial Officer, Zvi Ben-David, will retire on May 15, 2025. The company has appointed Chen Franco-Yehuda as the new CFO, Treasurer, and Secretary, effective upon Ben-David's retirement.
Pluri Inc. announced a $6.5 million strategic investment and the acquisition of a 71% stake in Kokomodo Ltd., an AgTech company focused on cultivated cacao production. The transactions aim to strengthen Pluri's financial position and expand its leadership in sustainable food technologies.
Pluri Inc., a biotechnology firm, is facing the possibility of being delisted from the Nasdaq Capital Market due to failing to meet the minimum stockholders' equity requirement. The company has submitted a compliance plan and has been granted an extension until November 2024 to regain compliance.
HAIFA, Israel, June 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today announced strategic investments in Pluri’s subsidiary, Ever After Foods Ltd. (“Ever After Foods”), which offers a cutting-edge technology platform to produce cultivated food with unmatched, cost-efficient scalability. Ever After Foods is Pluri’s majority-owned joint venture with Israeli food giant Tnuva Food-Tech Incubator (2019), L.P. (“Tnuva”), and has exclusive licensing rights to use Pluri’s technology and intellectual property to develop, manufacture and commercialize cultivated meat. The $10 million funding round will propel Ever After Foods’ cost-advantageous and scalable technology platform, positioning it as a leading technology enabler.
HAIFA, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company), a leading biotechnology company that transforms cells into solutions, today announced the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has exercised its option for year two of the three-year $4.2 million contract it entered into with Pluri in July 2023. During the 12 months from July 1, 2024 through June 30, 2025, the NIAID will provide $1.4 million for the Company to manufacture the PLX-R18 cell therapy and to conduct both in vitro and in vivo studies to develop PLX-R18 as a potential novel treatment for hematopoietic complications of the acute radiation syndrome (H-ARS).
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.